{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'ADAs: The actual sample collection date and exact time will be entered on the', 'Immunogenicity Blood Collection eCRF page. Sampling problems will be noted in', 'the Comments section of the eCRF. All blood samples will be taken by either direct', 'venipuncture or an indwelling cannula inserted in a forearm vein. A Laboratory', 'Manual will be provided to the Investigators with detailed information on sample', 'collection, handling and shipment. Tubes and preprinted labels will be provided by', 'the central laboratory to the study sites.', 'Details regarding collection of samples, shipment of samples, reporting of results, laboratory', 'reference ranges, and alerting abnormal values will be supplied to the study site before study', 'site initiation in a Laboratory Manual.', \"The laboratory sheets will be filed with the subject's source documents.\", '7.4.6.2', 'Mandatory Retesting of Laboratory Abnormalities', 'The following laboratory abnormalities require prompt retesting after the initial abnormal', 'result is reported to the study site (within 72 hours of receiving abnormal LFT results and', 'within 5 days of receiving all other abnormal results):', 'Any single ALT and/or AST elevation >3x ULN, regardless of total bilirubin (repeat', 'laboratory testing must include total bilirubin, direct and indirect bilirubin, GGT, INR,', 'alkaline phosphatase, creatine phosphokinase, and hematology assessment)', 'Neutrophil count <1000x106/L (<1000/mm\u00b3)', 'Lymphocyte count <500x106/L (<500/mm\u00b3)', 'Platelet count <100,000 platelets/mm\u00b3', 'Any single hemoglobin value <8.0g/dL or one that drops >20 g/L (2 g/dL) below', 'OLE Baseline', 'Clinically significant laboratory abnormalities should be re-tested and followed until', 'resolution, stabilization, or return to baseline values and information will be recorded on the', 'appropriate pages of the eCRF.', '7.4.7', 'Vital Signs, Physical Findings, and Other Safety Assessments', '7.4.7.1', 'Physical Examination', 'A complete physical examination will be performed at Visit 1 (OLE Baseline/Week 24),', 'Visit 6 (Week 52), Visit 10 (EoT/Week 106), and Safety Follow-Up Visit SFU-3', '(Week 126), as indicated in Table 1. A complete physical examination will include', 'Amendment 2: 06 March 2019', '114', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'evaluation of general appearance, skin, head, eyes, ears, nose and throat, lymph nodes,', 'respiratory, CV, GI including hepatobiliary assessment, musculoskeletal, endocrine system,', 'neurological systems, and urogenital system.', 'At all other visits, a partial physical examination will be performed assessing the following:', 'general appearance, skin (including site of study treatment injection), respiratory, CV, and', 'GI.', 'All significant findings that are present at OLE Baseline must be reported on the \"Adverse', 'Events Ongoing from Core Study\" page of the eCRF. Significant findings detected after', 'randomization to the OLE study that meet the definition of an AE must be recorded on the', 'relevant \"Adverse Event\" page of the eCRF.', '7.4.7.2', 'Vital Signs', 'Vital signs (temperature, heart rate, BP, and respiratory rate) will be measured as indicated in', 'Table 1, and when clinically indicated. Whenever possible, vital sign assessments should be', 'performed by the same study site staff member and using the same validated device(s)', 'throughout the study. Blood pressure and heart rate should be measured after the subject', 'rests 5 minutes in a sitting position.', 'Not every vital sign abnormality qualifies as an AE. A vital sign result should be reported as', 'an AE if it meets any of the following criteria:', 'Results in a change in RA treatment (e.g., dosage modification, treatment interruption,', 'or treatment discontinuation)', 'Results in a medical intervention or a change in concomitant therapy', \"Clinically significant in the Investigator's judgment\", \"It is the Investigator's responsibility to review all vital sign findings. Medical and scientific\", 'judgment should be exercised in deciding whether an isolated vital sign abnormality should', 'be classified as an AE.', '7.4.7.3', 'Body Weight and Height', 'Body weight (to the nearest 0.1 kilogram [kg]) and height (in cm) will be recorded at the time', 'points specified in Table 1. Body weight and height should be measured in indoor clothing', 'without shoes. Whenever possible, body weight measurement should be performed by the', 'same study site staff member and using the same validated scale throughout the study. The', \"subject's body mass index will be calculated automatically in the eCRF.\", 'Amendment 2: 06 March 2019', '115', 'Confidential']\n\n###\n\n", "completion": "END"}